Bristol Myers Squibb - 50 Year Stock Price History | BMY

Historical daily share price chart and data for Bristol Myers Squibb since 1972 adjusted for splits. The latest closing stock price for Bristol Myers Squibb as of September 29, 2022 is 71.71.
  • The all-time high Bristol Myers Squibb stock closing price was 79.42 on June 27, 2022.
  • The Bristol Myers Squibb 52-week high stock price is 80.59, which is 12.4% above the current share price.
  • The Bristol Myers Squibb 52-week low stock price is 53.22, which is 25.8% below the current share price.
  • The average Bristol Myers Squibb stock price for the last 52 weeks is 68.60.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Bristol Myers Squibb Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2022 71.4636 60.4669 79.4230 60.4669 71.7100 17.70%
2021 60.8311 58.5962 67.1710 52.4053 60.9262 2.89%
2020 56.8024 58.6180 62.4031 42.9409 59.2167 0.39%
2019 45.5508 46.5313 58.9856 38.9797 58.9856 27.86%
2018 50.7487 52.9959 60.0120 43.2742 46.1319 -12.91%
2017 49.2814 50.0250 56.4881 39.6571 52.9700 7.72%
2016 52.6699 55.3929 64.1542 41.4252 49.1751 -13.50%
2015 52.5801 48.0632 58.1164 46.8022 56.8474 19.24%
2014 41.4718 41.0618 49.2024 36.8551 47.6755 14.18%
2013 33.8544 24.9218 42.0106 24.9218 41.7531 69.95%
2012 24.7242 25.3668 26.9779 23.2257 24.5675 -3.78%
2011 20.6436 18.3821 25.5697 17.4874 25.5334 39.43%
2010 17.4286 17.0939 19.0925 15.1453 18.3130 8.74%
2009 14.0237 15.0699 17.1003 11.0500 16.8405 14.78%
2008 13.1798 15.5696 16.1357 10.7466 14.6723 -6.05%
2007 16.7336 15.1014 18.7497 14.9412 15.6168 4.75%
2006 13.4350 12.5725 14.9088 11.3359 14.9088 19.92%
2005 12.8779 13.1493 13.9987 11.3769 12.4318 -6.16%
2004 12.7801 14.6613 15.3057 11.4993 13.2476 -7.27%
2003 12.2949 11.4938 14.2867 10.1067 14.2867 29.02%
2002 14.3409 23.3015 23.5077 9.5957 11.0729 -52.36%
2001 25.9334 31.9747 31.9747 22.3308 23.2423 -29.71%
2000 25.8575 28.3460 33.0658 19.2144 33.0658 17.11%
1999 29.8280 28.3124 34.2844 25.1075 28.2360 -2.80%
1998 23.4676 20.3252 29.0506 19.2899 29.0506 42.93%
1997 16.2042 11.2787 20.9225 11.2787 20.3252 77.07%
1996 9.5145 8.6607 12.1052 8.2078 11.4788 32.15%
1995 6.8683 5.7770 8.7112 5.6918 8.6860 53.27%
1994 5.3024 5.3399 5.8616 4.7681 5.6673 6.10%
1993 5.2625 5.8661 5.8661 4.6306 5.3417 -9.48%
1992 6.1813 7.4850 7.5274 5.3803 5.9011 -21.16%
1991 6.6045 5.4799 7.4850 5.0481 7.4850 35.83%
1990 4.7549 4.5031 5.5224 4.0467 5.5104 24.55%
1989 3.8293 3.3669 4.4710 3.3381 4.4241 28.87%
1988 3.1971 3.2453 3.4517 2.8889 3.4329 9.89%
1987 3.5788 3.1654 4.1270 2.7388 3.1238 0.77%
1986 2.8397 2.4668 3.2967 2.2654 3.0998 24.71%
1985 2.1988 1.9228 2.5370 1.8665 2.4856 26.48%
1984 1.7405 1.6182 1.9697 1.5664 1.9652 23.97%
1983 1.4567 1.2569 1.7870 1.1818 1.5852 25.65%
1982 1.1150 0.9895 1.3741 0.9592 1.2616 26.58%
1981 0.9820 0.9567 1.0974 0.8654 0.9967 5.46%
1980 0.7638 0.6825 0.9638 0.5768 0.9451 36.16%
1979 0.6482 0.6682 0.7175 0.5862 0.6941 3.50%
1978 0.6317 0.6262 0.7457 0.5299 0.6706 6.29%
1977 0.6110 0.6378 0.6682 0.5417 0.6309 -1.99%
1976 0.6858 0.6495 0.7762 0.5803 0.6437 -0.36%
1975 0.5824 0.4795 0.6905 0.4420 0.6460 37.39%
1974 0.4358 0.4385 0.5265 0.2966 0.4702 8.12%
1973 0.5736 0.6425 0.6695 0.4127 0.4349 -32.80%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $153.119B $46.385B
Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, comprising other drugs like Revlimid, Pomalyst, Sprycel, Yervoy and Empliciti. It also has important immunology and cardiovascular drugs like Orencia and Eliquis. It's experiencing growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program. After the sale of the global Diabetes business to AstraZeneca and the discontinuation of discovery research efforts in virology, it's focusing solely on research in core therapeutic areas like oncology, immuno-oncology, immunoscience, cardiovascular, fibrosis and genetically defined diseases. It acquried Celgene Corporation and MyoKardia. It received regulatory approvals for Reblozyl and Inrebic.
Stock Name Country Market Cap PE Ratio
GSK (GSK) United Kingdom $59.709B 7.17
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
Biohaven Pharmaceutical Holding (BHVN) United States $10.856B 0.00
QIAGEN (QGEN) Netherlands $9.360B 15.67
Ginkgo Bioworks Holdings (DNA) United States $5.587B 0.00
Arcus Biosciences (RCUS) United States $1.842B 35.96
Myovant Sciences (MYOV) United Kingdom $1.684B 0.00
Emergent Biosolutions (EBS) United States $1.036B 6.01
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Enzo Biochem (ENZ) United States $0.107B 0.00
Gelesis Holdings (GLS) United States $0.078B 0.00
SQZ Biotechnologies (SQZ) United States $0.065B 0.00
Ambrx Biopharma (AMAM) United States $0.042B 0.00